Key result
Novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) present a convenient option for safe and efficacious thromboprophylaxis in post-arthroplasty patients.
Why the study?
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide safe and efficacious thromboprophylaxis compared to traditional anticoagulants in patients after elective hip and knee arthroplasty?
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide safe and efficacious thromboprophylaxis compared to traditional anticoagulants in patients after elective hip and knee arthroplasty?
Novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban offer a convenient, safe, and efficacious alternative to traditional anticoagulants for thromboprophylaxis following elective hip and knee arthroplasty.
May support NOAC consideration post-arthroplasty; leaves open need for randomized confirmation versus traditional agents.
Anticoagulant medications help to reduce the risk of thromboembolic events after total hip arthroplasty and total knee arthroplasty. Traditionally, this has been accomplished with medications, such as low-molecular-weight heparin and warfarin. However, these traditional anticoagulants possess a variety of shortcomings that leave much room for improvement. A new class of oral anticoagulants is now available, and present a more convenient option for safe and efficacious thromboprophylaxis in post arthroplasty patients, particularly in the outpatient setting. This review focuses on the direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, and the clinical data to date about their use in total hip arthroplasty and total knee arthroplasty patients.
No takes yet. Share an insight, caveat, or question.
Messerschmidt et al. (2015) conducted a review in Total hip and knee arthroplasty. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Low-molecular-weight heparin and warfarin was evaluated. Novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) present a convenient option for safe and efficacious thromboprophylaxis in post-arthroplasty patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: